HeartSciences, Inc. (HSCS)
2.74
-0.17
(-5.84%)
USD |
NASDAQ |
Dec 09, 16:00
2.74
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 7.255M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -31.53% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 469.79 |
| Price to Book Value | 2.310 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.6198 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| HeartSciences, Inc. is a medical technology company, which focuses on applying innovative AI-based technology to an electrocardiogram (ECG) to expand and improve an ECG's clinical usefulness. Its objective is to make an ECG a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. The firm offers MyoVista, a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction. The company was founded on August 16, 2007 and is headquartered in Southlake, TX. |
| URL | http://www.heartsciences.com |
| Investor Relations URL | https://ir.heartsciences.com/ |
| HQ State/Province | Texas |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| HeartSciences, Inc. is a medical technology company, which focuses on applying innovative AI-based technology to an electrocardiogram (ECG) to expand and improve an ECG's clinical usefulness. Its objective is to make an ECG a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. The firm offers MyoVista, a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction. The company was founded on August 16, 2007 and is headquartered in Southlake, TX. |
| URL | http://www.heartsciences.com |
| Investor Relations URL | https://ir.heartsciences.com/ |
| HQ State/Province | Texas |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |